Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial

Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial

Abstract Background Despite substantial illness burden and healthcare utilization conferred by pain from vaso-occlusive episodes (VOE) in children with sickle cell disease (SCD), disease-modifying therapies to effectively treat SCD-VOE are lacking. The aim of the Sickle Cell Disease Treatment with A...

Full description

Bibliographic Details
Main Authors: Chris A. Rees, David C. Brousseau, Daniel M. Cohen, Anthony Villella, Carlton Dampier, Kathleen Brown, Andrew Campbell, Corrie E. Chumpitazi, Gladstone Airewele, Todd Chang, Christopher Denton, Angela Ellison, Alexis Thompson, Fahd Ahmad, Nitya Bakshi, Keli D. Coleman, Sara Leibovich, Deborah Leake, Dunia Hatabah, Hagar Wilkinson, Michelle Robinson, T. Charles Casper, Elliott Vichinsky, Claudia R. Morris, the SCD Arginine Study Group and PECARN
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Trials
Subjects:
Sickle cell disease
Arginine
Vaso-occlusive pain
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-023-07538-z

Internet

https://doi.org/10.1186/s13063-023-07538-z

Similar Items